BIA calls for separate framework to evaluate drugs for rare diseases

The UK BioIndustry Association (BIA) has called for a separate framework to evaluate and commission medicines and treatments for rare and very rare diseases in response to NHS England (NHSE)’s consultation on investing in specialized services. The consultation opened in January and closes today.

The BIA said that while it welcomes the opportunity to contribute and comment on NHSE thinking on this important issue, its response raises several concerns and suggests that a different and distinct approach is required for the consideration of medicines and treatments for rare and very rare diseases.

The BIA proposes that: